Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418

dc.creatorPiesche, Matthias
dc.creatorMaucher, Isabelle V.
dc.creatorRühl, Michael
dc.creatorKretschmer, Simon B.M.
dc.creatorHofmann, Bettina
dc.creatorKühn, Benjamin
dc.creatorFettel, Jasmin
dc.creatorVogel, Anja
dc.creatorFlügel, Karsten T.
dc.creatorManolikakes, Georg
dc.creatorHellmuth, Nadine
dc.creatorHäfner, Ann-Kathrin
dc.creatorGolghalyani, Vahid
dc.creatorBall, Ann-Katrin
dc.creatorMatrone, Carmela
dc.creatorGeisslinger, Gerd
dc.creatorParnham, Michael J.
dc.creatorKaras, Michael
dc.creatorSteinhilber, Dieter
dc.creatorRoos, Jessica
dc.creatorMaier, Thorsten J.
dc.date2017-09-07T18:55:43Z
dc.date2017-09-07T18:55:43Z
dc.date2017
dc.date.accessioned2019-11-20T15:07:06Z
dc.date.available2019-11-20T15:07:06Z
dc.identifierhttp://repositorio.ucm.cl:8080/handle/ucm/124
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3031900
dc.descriptionRecently, we published that nitro-fatty acids (NFA) are potent electrophilic molecules which inhibit 5-lipoxygenase (5-LO) by interacting catalytically with cysteine residues next to a substrate entry channel. The electrophilicity is derived from an intramolecular Michael acceptor moiety consisting of an electron-withdrawing group in close proximity to a double bond. The potential of the Michael acceptor moiety to interact with functionally relevant cysteines of proteins potentially renders them effective and sustained enzyme activity modulators. We screened a large library of naturally derived and synthetic electrophilic compounds to investigate whether other types of Michael acceptor containing drugs suppress 5-LO enzyme activity. The activity was measured by assessing the effect on the 5-LO product formation of intact human polymorphonuclear leukocytes. We demonstrated that a number of structurally different compounds were suppressive in the activity assays and showed that Michael acceptors of the quinone and nitro-alkene group produced the strongest inhibition of 5-LO product formation. Reactivity with the catalytically relevant cysteines 416 and 418 was confirmed using mutated recombinant 5-LO and mass spectrometric analysis (MALDI-MS). In the present study, we show for the first time that a number of well-recognized naturally occurring or synthetic anti-inflammatory compounds carrying a Michael acceptor, such as thymoquinone (TQ), the paracetamol metabolite NAPQI, the 5-LO inhibitor AA-861, and bardoxolone methyl (also known as RTA 402 or CDDO-methyl ester) are direct covalent 5-LO enzyme inhibitors that target the catalytically relevant cysteines 416 and 418.
dc.languageen
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.sourceBiochemical Pharmacology, 125, 55-74
dc.subjectInflammation
dc.subjectEicosanoids
dc.subjectLeukotrienes
dc.subjectThymoquinone
dc.subjectElectrophilic molecules
dc.subjectCysteine
dc.titleMichael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución